Financial Performance - Q3 2025 revenue increased 54% year-over-year to $17.60 billion, driven by volume growth from Mounjaro and Zepbound[4] - Q3 2025 reported EPS rose to $6.21, up from $1.07 in Q3 2024, while non-GAAP EPS increased to $7.02 from $1.18[4] - The company raised its 2025 full-year revenue guidance to a range of $63.0 billion to $63.5 billion, with reported EPS guidance increased to $21.80 to $22.50[4] - Revenue for Q3 2025 was reported at $17,600.8 million, a 54% increase compared to $11,439.1 million in Q3 2024[37] - The net income for the nine months ended September 30, 2025, was $14,002.3 million, representing a 127% increase from $6,180.2 million in the same period of 2024[37] - Reported net income for Q3 2025 was $5,582.5 million, a significant increase from $970.3 million in Q3 2024[40] - Non-GAAP net income for Q3 2025 reached $6,311.9 million, compared to $1,064.5 million in Q3 2024, reflecting strong operational performance[40] - For the nine months ended September 30, 2025, reported net income was $14,002.3 million, up from $6,180.2 million in the same period of 2024[40] - Non-GAAP net income for the nine months ended September 30, 2025 was $14,995.6 million, compared to $6,941.0 million in 2024, showcasing strong growth[40] Product Performance - Mounjaro revenue grew 109% to $6.52 billion in Q3 2025, with U.S. revenue at $3.55 billion, a 49% increase[20] - Zepbound revenue in Q3 2025 increased 185% to $3.59 billion, primarily driven by increased demand[21] - Revenue outside the U.S. rose 74% to $6.30 billion, with a 66% increase in volume and a 6% favorable impact from foreign exchange rates[7] Expenses and Margins - Research and development expenses increased 27% to $3.47 billion, representing 19.7% of revenue, reflecting continued investments in the pipeline[9] - The gross margin as a percentage of revenue was reported at 82.9% for Q3 2025, compared to 81.0% for Q3 2024[38] - The expected performance margin is now between 43.5% and 44.5% on a reported basis, and between 45.0% and 46.0% on a non-GAAP basis[26] - The company incurred $364.9 million in asset impairment and restructuring charges in Q3 2025, compared to $81.6 million in Q3 2024[40] Regulatory and Strategic Developments - U.S. FDA approved Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer, marking significant regulatory progress[4] - The company announced new manufacturing facilities in Virginia and Texas, and an expansion of its Puerto Rico site to increase capacity[3] - Lilly plans to acquire Adverum Biotechnologies and invest over $1.2 billion in its Puerto Rico facility to enhance oral medicine manufacturing capacity[24] - The company completed the acquisition of Verve Therapeutics, Inc., which included litigation and integration costs, impacting financial results[41] Tax and Other Income - The effective tax rate remains unchanged at approximately 19% on a reported basis and 17% on a non-GAAP basis[27] - The effective tax rate for reported income was 22.8% in Q3 2025, down from 38.9% in Q3 2024[40] - The effective tax rate for non-GAAP income was 17.7% in Q3 2025, compared to 37.6% in Q3 2024, reflecting favorable tax adjustments[40] - Other income (expense) is now expected to be an expense in the range of $700 million to $600 million on a reported basis[29]

格隆汇10月30日｜礼来(LLY.US)：第三季度营收176亿美元，同比增长54%，预期为160.7亿美元；调整 后每股收益7.02美元，去年同期为1.18美元。礼来预计全年收入为630亿美元至635亿美元，之前预期为 600亿美元至620亿美元。礼来盘前涨超7%。 ...

格隆汇10月30日｜礼来(LLY.US)盘前涨超7%。消息面上，礼来预计全年收入为630亿美元至635亿美 元，之前预期为600亿美元至620亿美元。 ...

Eli Lilly raises its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat analysts’ estimates in the third quarter https://t.co/MdyjurUDYZ ...

Core Insights - Eli Lilly raised its full-year profit and revenue forecast due to strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro, leading to a third-quarter earnings beat [1][3] - The company's shares increased by 2% in early trading following the announcement [1] - The weight-loss drug market is projected to reach $150 billion by the end of the decade, with Eli Lilly competing with Novo Nordisk for market leadership [1] Financial Performance - Eli Lilly expects adjusted earnings of $23.00 to $23.70 per share for the year, an increase from the previous forecast of $21.75 to $23.00 per share [3] - For the third quarter, the company reported earnings of $7.02 per share on an adjusted basis, surpassing analysts' average estimate of $5.69 per share [5] Market Context - Investors have high expectations for Eli Lilly's GLP-1 portfolio amid concerns over potential U.S. price negotiations [2] - The U.S. government is implementing a "most favored nation" policy to align domestic drug prices with those in other wealthy nations [2]

Core Insights - Eli Lilly has raised its full-year profit and revenue forecast, driven by increasing demand for its GLP-1 drugs [1] Company Summary - The company is experiencing a surge in demand for its blockbuster GLP-1 drugs, which has led to an optimistic outlook for the year [1] Industry Summary - The performance of Eli Lilly reflects a broader trend in the pharmaceutical industry, particularly in the market for GLP-1 medications, which are gaining popularity [1]

Core Insights - Eli Lilly reported third-quarter earnings and revenue that exceeded analyst expectations, driven by strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro [1][3] - The company raised its full-year outlook, indicating confidence in continued growth in the GLP-1 drug market [1] Financial Performance - Adjusted earnings per share were $7.02, surpassing the expected $5.69 [3] - Revenue reached $17.60 billion, exceeding the anticipated $16.01 billion [3] Market Position - Eli Lilly is focused on maintaining its competitive edge over Novo Nordisk in the rapidly growing market for GLP-1 obesity and diabetes drugs [1]

Core Insights - Eli Lilly reported a strong third-quarter performance for 2025, achieving a 54% year-over-year revenue growth driven by high demand for its incretin portfolio, particularly Mounjaro and Zepbound [2][3][7]. Financial Performance - Total revenue for Q3 2025 reached $17.60 billion, up from $11.44 billion in Q3 2024, reflecting a 54% increase [3][7]. - Net income for Q3 2025 was $5.58 billion, compared to $970.3 million in Q3 2024, marking a significant increase [12][40]. - Earnings per share (EPS) rose to $6.21 on a reported basis and $7.02 on a non-GAAP basis, compared to $1.07 and $1.18 respectively in Q3 2024 [12][14]. Revenue Breakdown - U.S. revenue increased by 45% to $11.30 billion, driven by a 60% increase in volume, despite a 15% decrease due to lower realized prices [4][7]. - International revenue surged by 74% to $6.30 billion, primarily due to a 66% increase in volume and a 6% favorable impact from foreign exchange rates [5][7]. Key Product Performance - Mounjaro's revenue grew by 109% to $6.52 billion, with U.S. sales reaching $3.55 billion, a 49% increase [17]. - Zepbound's revenue in the U.S. increased by 184% to $3.57 billion, driven by heightened demand [18]. - Verzenio's worldwide revenue rose by 7% to $1.47 billion, with U.S. revenue slightly up to $880.3 million [19]. Pipeline and Regulatory Developments - Eli Lilly advanced orforglipron through four additional Phase 3 trials, with plans for global obesity submissions by year-end [2][7]. - The U.S. FDA approved Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer, marking a significant regulatory achievement [7][20]. Manufacturing and Capacity Expansion - The company announced new manufacturing facilities in Virginia and Texas, along with an expansion of its site in Puerto Rico to increase production capacity [2][7][28]. Financial Guidance - Eli Lilly raised its full-year revenue guidance to a range of $63.0 billion to $63.5 billion, reflecting strong business performance and favorable foreign exchange rates [25][27]. - The updated EPS guidance is now projected to be between $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis [27][30].

Core Insights - Eli Lilly's weight loss drug Zepbound will be available at Walmart pharmacies nationwide through a direct-to-consumer program starting next month [1] - The direct-to-consumer platform, LillyDirect, aims to enhance affordability and accessibility of Zepbound by allowing consumers to purchase directly from Eli Lilly without insurance [2] - Eli Lilly has reduced the cost of certain Zepbound doses by at least 50%, with the starting dose priced at $349 per month, compared to a list price of $499 for other doses [3] Availability and Accessibility - The partnership with Walmart enables patients with valid prescriptions to pick up Zepbound at pharmacies or opt for home delivery [1] - The drug's popularity has increased since its FDA approval in 2023, but access has been complicated by insurance coverage issues [4][10] - Even with insurance, prior authorization is often required, which includes specific criteria such as BMI thresholds and prior treatment attempts [10] Drug Classification and Efficacy - Zepbound is approved for chronic weight management in adults with obesity or overweight conditions and is classified as a GLP-1 agonist, similar to Novo Nordisk's Wegovy and Ozempic [7] - Studies indicate that Zepbound may also reduce the risk of Type 2 diabetes [5]

Core Viewpoint - Eli Lilly is set to report its third-quarter results, with significant attention on the potential deal regarding the pricing of its weight-loss drug with the Trump administration [1] Company Summary - Eli Lilly is a drugmaker preparing to announce its financial performance for the third quarter [1] - The company faces uncertainty regarding the negotiations with the Trump administration over the pricing strategy for its weight-loss drug [1] Industry Summary - The pharmaceutical industry is closely monitoring Eli Lilly's upcoming results and the implications of its pricing negotiations, which could set precedents for other companies in the sector [1]